Current status of hormone therapy
Hormone therapy is an effective treatment for prostate cancer, and the only initial systemic treatment available for the man with advanced disease. 1 Many would consider treatment mandatory in M1 disease, certainly if it is symptomatic. In locally advanced disease there is increasing evidence for an improved survival benefit, although whether this is best achieved by monotherapy 2 or as adjuvant treatment following radiotherapy 3 requires further elucidation. Treatment is being instituted earlier in the disease. This is a result of the stage shift produced by PSA testing, with increasing numbers of patients with localised disease in whom 'curative' treatment has failed. 4 There is also an interest in exploring the merits of adjuvant treatment 5 -the urological equivalent of tamoxifen in breast cancer.
On the other hand, there is also an increasing awareness of the toxicity of hormonal therapy, which has to be balanced against any benefits. 6 The decision when to start therapy and which treatment to use depends on the balance of benefit and risk.
Advanced prostate cancer Immediate vs deferred treatment
The results of MRC trial PR03 comparing immediate vs deferred treatment were first published in 1997. 2 The conclusions then were that immediate treatment delayed death from prostate cancer although there was less improvement in overall survival. Progression of disease was delayed, both development of distant metastases and local progression as measured by the number of TURPs performed and the incidence of ureteric obstruction. There was a reduction in the incidence of complications; spinal cord compression, pathological fracture and extra skeletal metastases. The current status of MRC PR03 (as in June 2003) is indicated in Table 1 . Since the majority of patients have now died, the data are now mature and unlikely to change significantly in future.
As before, there remains a highly significant improvement in disease-specific survival in those treated immediately (Figure 1a) . However, although the overall survival is also improved, the difference is not significant (Figure 1b) . This apparent discrepancy is a familiar finding, and was also seen in the recently published Scandinavian Radical Prostatectomy Study 7 in which the deaths from prostate cancer were halved, from 31 to 16 (p ¼ 0.02), but the reduction in overall survival (from 62 to 53) was not statistically significant ( Figure 2) . As a result, the comments listed in Table 2 were made. These assume erroneously that where a difference is not significant (ie p40.05) this is proof of no difference. The true interpretation should perhaps be somewhat different (R Peto, personal communication).
Prostate cancer occurs in an elderly population, who will experience comorbidity, and have a reduced life expectation (Table 3) . Even if their survival from prostate cancer is similar, as men get older, their overall survival, the product of life expectation and the prostate cancer survival, will decrease. Thus, an intervention which will significantly extend prostate cancer survival and will clearly improve the overall survival of a group of 60 y olds will have a negligible effect on that of men in their 80s. It is this effect of age and comorbidity which reduces the statistical significance of overall survival because of the high number of coincidental deaths. Trials large enough to demonstrate differences in disease-specific survival are underpowered for overall survival, and thus are erroneously ascribed a negative interpretation.
If a reduction in prostate cancer deaths is not to affect overall survival, there would have to be a treatment induced increase in deaths from other causes. This was indeed the case in patients treated with oestrogens, due to an increased risk of cardiovascular death, but no such effect is apparent on meta-analysis of many trials using orchiectomy or LHRH analogues, 8 nor is such an effect apparent in MRC PR03 (Figure 1c ). Improved survival from prostate cancer should be seen as a bonus on top of the patients' other risks of dying but one which will only be realised by a small proportion of men in their 80s.
Other benefits from hormone treatment
In 1997, results from PR03 demonstrated a reduction in complications in those treated immediately. Although in many cases, these complications, particularly spinal cord compression, occurred in the deferred treatment group after treatment had already been started for another unrelated cause, it was possible, as the data matured, that they would appear more frequently in the immediate treatment group, who would 'catch up'. This does not seem to have happened (Table 4) , and suggests that tumour progression, taking place during the period for which treatment is deferred, may not be fully reversible. New data, consistent with this, show that the number of men who develop metastatic pain at any stage of the disease is reduced in those treated immediately. The reduction in these events has clear quality of life benefits to set against the disadvantages of hormone therapy.
Choice of hormone therapy
Compared to 50 y ago, when the only choice available was between orchiectomy and oestrogen treatment, the modern urologist and his patient have several options. These produce different endocrine changes (Table 5) , which influence their potential side effects, and possibly their relative efficacy. It is generally accepted that LHRH analogues are equivalent therapeutically to earlier methods of hormone treatment. Is this really the case? The clinical trials which are accepted to demonstrate Overall survival is the product of the 10 y mortality from prostate cancer and the age-related survival for other causes of death. Androgen ablation D Kirk Androgen ablation D Kirk this, 9-12 all involved comparatively small numbers of patients-numbers too small to conclusively exclude a difference which might be clinically significant ( Table 6 ). The large randomised trial necessary to prove this point will never be done, so likely equivalence in efficacy must be accepted. However, there could be men who do not have their testosterone suppressed to castrate levels by LHRH analogues, and this should be considered if a patient does not respond to treatment as expected.
Androgen deprivation
Accepting the comments in the previous section, orchiectomy and LHRH analogues generally produce equivalent reductions in testosterone. Orchiectomy involves an operation and potential surgical complications. Whether 'castration' produces the psychological problems often assumed is less clear. Most urologists will do a subcapsular orchiectomy which reduces the size of the testis rather than removing it. There are clear advantages in terms of compliance, and although the procedure is irreversible, there must be few occasions when this will matter. LHRH analogues have the problem of tumour flare, 13 and most users will recommend flare prevention with an antiandrogen. The need for continuing injections may over a long period cancel out the disadvantage of an operation, and occasional drug idiosyncrasies occur.
Whether achieved by orchiectomy or use of LHRH analogues, reduction in serum testosterone has a number of adverse effects. In addition to the immediate problems with sexual dysfunction 14 and hot flushes, 15 in the medium term, patients experience weight increase and loss of muscle mass. 16 Patients can become anaemic, and recently, it has been recognised that there can also be a loss of cognitive function. 17 Perhaps the most serious problem is osteoporosis, with an increased incidence of pathological fractures not due to metastases. 18 Previously a problem not recognised in men, osteoporosis can occur with nonmetastatic prostate carcinoma. Rate of bone loss is increased by androgen deprivation but is more likely to occur in elderly men with pre-existing risk factors, such as age and smoking. Most significantly, in view of the trend towards earlier use of hormonal treatment, is the relation to duration of treatment.
Strategies to reduce morbidity
How can these problems be prevented? Possible strategies include use of alternative drugs, such as antiandrogens or oestrogens, reducing the toxicity of the latter either by use in low dosage combined with aspirin, or by parenteral administration avoiding the initial metabolism in the liver, believed to be the source of the toxicity. Avoidance of toxicity is a major motive for deferring treatment. Intermittent therapy aims not only to reduce toxicity but also delay the onset of hormone refractory disease.
Although bisphosphonate treatment is used principally to modify the development of metastatic disease, 19 these drugs will also help prevent osteoporosis. 20 are less likely to produce hot flushes and indeed are used to treat these. However, they have their own problems and are associated with fatigue and mood changes but most importantly, can cause occasional but often fatal liver toxicity, to the extent that they are no longer recommended for long-term use in prostate cancer. Nonsteroidal antiandrogens, 21 licensed for use in locally advanced disease, have been advocated as a method of avoiding sexual dysfunction, but with conflicting results, and there is evidence that they do not affect bone density. However, other side effects occur, notably GI disturbances (mainly a problem with flutamide), gynaecomastia or breast soreness which occurs in a substantial number of men taking bicalutamide, and hot flushes. They also can cause liver toxicity.
Oestrogens
Following the cardiovascular toxicity data revealed in the VACURG studies, 22 the use of diethylstilboesterol (DES) and other oestrogens almost completely stopped. Periodically, interest returns, 23 and clearly, if it were not for their toxicity, they would have a number of advantages. Since testosterone suppression occurs by substitution with another steroid hormone, hot flushes and osteoporosis are unlikely. They produce an increase in serum hormone binding globulin (SHBG) and possibly have direct tumour suppression effects, so may be more effective as actual cancer therapy. However, these potential advantages are counteracted by their recognised toxicity-gynaecomastia, cardiovascular/thromboembolic effects (related to changes in plasma lipids, platelet aggregation and reduction of antithrombin III) fluid retention and liver toxicity Can the toxicity of oestrogens be reduced to allow their potential advantages to be realised? One strategy is a combination of a low dose (eg DES 1.0 mg daily) 23 combined with aspirin. This has regularly been proposed as a regime worthy of clinical trial, but such a trial has yet to emerge. The toxicity of oestrogens is said in part result from oestrones produced in the liver, and may be avoided by parenteral administration. 24 The depot injection polyestradial phosphate was used in a Scandinavian study, 25 which demonstrated equivalent efficacy, but although there was no excess in cardiovascular mortality, the number of cardiovascular adverse events was increased. Oestrogen preparations are becoming more difficult to obtain, although a simple method of parenteral administration could be to use oestrogen skin patches. 26 Other hormone strategies
Combined androgen blockade
After over a decade of intense investigation, combined use of LHRH analogue and antiandrogen as first-line hormone treatment seems to find little favour, at least in the UK. Although the Prostate Cancer Trialists' Collaborative Group's second meta-analysis published in 2000 27 did show a statistically significant survival benefit, this was small, and generally seems not to be thought clinically worthwhile.
Intermittent hormone therapy 28 As described above, it is proposed that periods off treatment will not only reduce toxicity but might delay hormone insensitivity. Response and progression during the off treatment period are monitored with PSA. In metastatic disease, a single treatment cycle may approach the duration of response in many patients. The author also has some concern as to the reliability of PSA as a measure of relapse after hormone treatment. Although published studies have defined rational regimes for intermittent therapy, randomised comparison with conventional hormone treatment is needed to define its role-until then it must be considered as an investigational regime.
Endocrine therapy-the future
Hormonal therapy is a significant and potent treatment for prostate cancer, but one limited by its toxicity and the inevitable development of hormone refractory disease.
Although newer drugs offer promise we are far from having the perfect agent. A combination of less toxic drugs, and an understanding of the mechanisms of androgen insensitivity and prevention of hormone refractory disease would herald a new era in endocrine therapy. At present, despite enthusiasm for using drugs earlier in the disease, we are some way from having a urological equivalent of tamoxifen.
Hormonal treatment in 2004
There seems a general consensus that treatment is indicated on diagnosis of M1 disease. Deferred treatment is likely to be needed early, and the increased risk of serious complications noted in PR03 was mainly in the M1 patients. While in M0 disease, immediate treatment seems to improve local and distant disease control and may produce a survival advantage, this has to be balanced against the risk of toxicity in what may be a prolonged period of treatment. In practice, each patient has to be considered individually and should be involved himself in the decision. His age and health and aspirations are all important. Deferred treatment remains an option in many, selected patients, but the patient's compliance is essential, with careful follow-up, with prompt treatment on signs of significant progression. Availability of PSA as an early warning of rapidly progressive disease may have increased the safety of deferred treatment.
The immediate vs deferred treatment debate
New data from the EORTC is expected soon, as are the results of a meta-analysis by the Prostate Cancer Trialists' Collaborative Group. Meanwhile, the following points can be made on the basis of current information.
(1) Immediate hormone treatment does have an impact on advanced prostate cancer.
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(2) Immediate treatment reduces, not simply delays, significant complications. (3) Disease progression during the deferred period may not be completely reversible. (4) Disease-specific survival is improved. (5) The lack of statistically significant overall survival benefit in individual trials may simply reflect the expected mortality from other diseases in men surviving longer from prostate cancer. (6) Even if a reduction in prostate cancer mortality is at the expense of an increase in deaths from other causes, and death is not delayed, it might be better to die from a myocardial infarction than from prostate cancer.
